Immunomodulators - Part A

Name: Immunomodulators - Part A
Price: 327.95 AUD
Availability: OutOfStock
ISBN: 9780443345210

Rossen Donev (Head of Research, MicroPharm Limited, UK)

$327.95

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We will update you on expected arrival time to us. If this delay is too long, please let us know within 2 business days and we can give you options regarding cancelling or adjusting your order. More details on cancelling your order can be found in our Terms of Trade.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
22 May 2026

Biophysics; Biochemistry; Molecular biology

Series: Advances in Protein Chemistry and Structural Biology

Immunomodulators

Series edited by: Rossen Donev (Head of Research MicroPharm Limited UK)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 229mm, Width: 152mm,
Weight: 450g
ISBN: 9780443345210
ISBN 10: 044334521X
Series: Advances in Protein Chemistry and Structural Biology
Pages: 380
Publication Date: 22 May 2026
Audience: Professional and scholarly , Undergraduate
Format: Hardback
Publisher's Status: Active

1. Marine-Derived Polysaccharides and Peptides as Next-Generation Immunomodulators: Molecular Mechanisms, Therapeutic Potential, and Translational Challenges Selvaraj Chandrabose Sr. 2. Advances in Immunomodulation: From Dietary Influence to Computational Precision Karthick Vasudevan, Prasanna Kumar Selvam and Supraja Mohan 3. iPSC-derived immunotherapy for Tau and Alzheimer's disease Subashchandrabose Chinnathambi 4. Antibodies targeting amyloid-β and Tau oligomers in Alzheimer's Disease Subashchandrabose Chinnathambi 5. Biosimilars: Antibody and Nanobody Based Therapeutic Approaches Towards Protein Misfolding Diseases Subashchandrabose Chinnathambi and Nagaraj Rangappa 6. Immunomodulator drugs: mechanisms of action and systemic effects Vijay Kumar Prajapati 7. Microbiome and microbial products as immunomodulators: implication for gastrointestinal cancers Vijay Kumar Prajapati 8. Integration of Network pharmacology, docking, and dynamics analysis to investigate the immunomodulatory activity of Pongamia pinnata George Priya Doss C 9. Transcriptomic Insights into Epigenetic and Immunomodulatory Roles of Nuclear Histone Genes in Bladder Cancer: A bioinformatics Approach George Priya Doss C, Mangesh R, Santhosh Elavarasu, Insha Asheem, Nihla M, Udhaya Kumar and Sasikumar K 10. Utilizing DREIMT Database for Drug Prioritization in Immunomodulatory Therapy for Psoriasis and Psoriatic Arthritis George Priya Doss C 11. Targeting Immune Modulation Genes in Mpox. A Therapeutic Approach Using Natural Compounds George Priya Doss C 12. Identification of Common Hub Genes and Pathways in Systemic Lupus Erythematosus and Cervical Cancer Using Bioinformatics Approach George Priya Doss C, Tamizhini Loganathan and Hatem Zayed 13. Transcriptomic Profiling Reveals Immune Pathway Dysregulation and Key Interferon-Responsive Genes in Systemic Lupus Erythematosus Karthick Vasudevan, Prasanna Kumar Selvam and Supraja Mohan 14. TBC* Edeildo Ferreira da Silva-Júnior 15. TBC* Edeildo Ferreira da Silva-Júnior 16. Synthetic Immunomodulators: Revolutionizing Immunotherapy Ajaz Ahmad Bhat 17. Therapeutics Immunotargets for Tauopathy Subashchandrabose Chinnathambi 18. Antioxidants as immunomodulators for Tau and Amyloid-β in Alzheimer's disease Subashchandrabose Chinnathambi 19. VISTA as a double-edged immune checkpoint molecule in cancer and autoimmunity Sibel Kalyoncu Uzunlar

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.